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Abstract
Background: Healthcare workers (HCWs) represent a tuberculosis (TB) risk group for a wide range of tasks in
healthcare, even in countries with low TB incidence, like Italy. Latent Tuberculosis Infection (LTBI) screening
programs are an important tool for TB prevention in these setting.
Methods: A retrospective study under a LTBI screening program among HCWs at the Siena University Hospital
(Italy), was conducted between September 2011 and July 2015. Tuberculin Skin Test (TST) was used as a first level
examination; all TST-positive cases were tested with QuantiFERON-TB Gold In-Tube (QFT-GIT) test, together with a
group of TST-negative subjects.
Results: Among the 2136 HCWs screened, 144 (6.7 %) were TST-positive and therefore tested with QFT-GIT,
confirming a positive result in 36 cases (25 %). Agreement between two tests was poor (k = 0.092; 95 %, Confidence
Interval [CI]- 0.048–0.136, p = 0.002). Among TST-positive cases, discordant results occurred more frequently in BCG
vaccinated than unvaccinated HCWs (86.3 %, p < 0.001). The probability of a QFT-GIT-positive result increased
according to the TST diameter (p = 0.001). No putative risk factor was associated with LTBI occurrence.
Conclusions: The use of QFT-GIT test as a second step in TST-positive cases offers an appropriate tool for LTBI
detection, especially among BCG-vaccinated HCWs.
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Background
Healthcare workers (HCWs) are an important group at
increased risk for exposure to various infectious agents
including Mycobacterium tuberculosis. Probability of
exposure to tuberculosis (TB) infection depends on the
specific tasks and settings; for this reason HCWs are
stratified in different risk levels and should be included
in TB screening programs [1, 2].
Systematic testing for diagnosis of Latent Tuberculosis
Infection (LTBI) is an important component of infection
control strategies among HCWs [3]. LTBI is a state of
immune response to stimulation by M. tuberculosis anti-
gens without evidence of clinically manifested active TB
[3]. The lifetime risk of TB reactivation in case of LTBI is
estimated to be 5–10 %, decreasing over the years depend-
ing on several factors, the most important one being the
immunological status of the host [3, 4]. In many high-
income countries, periodic screening of HCWs and
contacts of confirmed TB patients for LTBI is a routine
component of TB control, including routinely repeated
screening or tracing after accidental contact with infected
patients or materials.
Until the introduction of Interferon Gamma Release
Assays (IGRAs), the only method for LTBI detection was
Tuberculin Skin Test (TST). TST is based on an intra-
dermal injection of a purified protein derivative (PPD)
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from M. bovis to elicit T-cell mediated delayed-type
hypersensitivity reaction if the person has been previ-
ously infected with M. tuberculosis. However, TST assay
has several intrinsic limitations: i) low sensitivity; ii)
subjective interpretation of results; iii) cross reaction
with Bacillus Calmette-Guerin (BCG) vaccination and
non-tuberculous mycobacteria (NTM) infections iv)
booster phenomenon [5–8]. The interpretation of TST
results in the serial testing of HCWs is a major issue:
findings show TST reversions or unclear conversions
resulting from either random variability (e.g., differences
in administration, reading or biologic response), boost-
ing effect or an actual new infection [9–12].
IGRAs overcome some of these shortcomings and have
emerged as an alternative to TST. IGRAs are indeed ex-
vivo blood-based tests, are not affected by BCG vaccin-
ation status and by most infections with environmental
NTM, can be repeated any number of times without
sensitization or boosting, require only one patient visit
and the result is available within 24 h.
To date, there are two commercial IGRAs, the Quanti-
FERON®-TB Gold In-Tube (QFT-GIT, QIAGEN, Hilden,
Germany) test that measures by ELISA assay the amount of
IFN-γ released by circulating T cells and the T-SPOT®.TB
assay (Oxford Immunotec Ltd, Abingdon, UK) which
assesses by enzyme-linked immunospot (ELISPOT) the
number of blood cells releasing IFN-γ. The antigens used
in QFT-GIT (ESAT-6, CFP-10 and TB7.7), are present in
M. tuberculosis but absent from the BCG vaccine strain
and from most NTM, except for M. kansasii, M. marinum,
M. szulgai, M. flavescens, and M. gastrii. Thus, the proteins
used as test antigens offer greater specificity compared to
TST [13, 14].
Different protocols for LTBI diagnosis combining TST
and IGRAs are currently used worldwide but the optimal
screening strategy is still debated. In the United States, the
Centers for Disease Control and Prevention (CDC,
Atlanta, GA) have suggested that IGRAs can be used in
place of TST for detection of TB infection [1]. However,
there are only limited data on the reproducibility of
IGRAs during serial testing. Studies have documented
conversions and reversions during repeated IGRAs and
there is no consensus on how to define and interpret these
phenomena [6, 15–17]. In the United Kingdom, the Na-
tional Institute for Health and Clinical Excellence (NICE)
guidelines recommend a two-step strategy for LTBI diag-
nosis based on the initial screening with TST followed by
an IGRA in TST-positive cases [18, 19].
With an overall TB incidence of 5.7 per 100,000 inhabi-
tants, Italy is considered among those countries at low TB
incidence. WHO guidelines indicate that in high-income
and upper middle-income countries, with low TB inci-
dence, systematic testing of LTBI, using IGRAs or TST,
should be considered for HCWs [3]. However, in countries
like Italy where until recently BCG vaccination has been
widely used in HCWs, surveillance of TB infection has
been hampered by the low specificity of TST. Current
Italian guidelines for LTBI screening among HCWs recom-
mend TST as primary assay, that can be integrated with
IGRAs in the case of TST positive result [20].
The present work is a retrospective study under a LTBI
screening program among HCWs at the Siena University
Hospital (Italy) based on the initial screening with TST
followed by QFT-GIT assay in TST-positive cases. The
agreement between the two tests, the LTBI prevalence
among Siena’s hospital HCWs and the identification of
putative risk factors for LTBI, were analyzed.
Methods
A screening program for TB was carried out from
September 2011 at the Siena University Hospital that is a
low TB risk level hospital. According to this program, all
HCWs and students with access to the health profession
school, undergo TST as first step examination, followed
by QFT-GIT in the case of TST-positive result. TST is
repeated yearly in HCWs serving high risk wards, such as
Infectious Diseases ward and Microbiology Laboratories.
A total of 2136 HCWs were screened from September
2011 to July 2015 by TST. All TST-positive individuals
(n = 144), as well as a control group of randomly selected
subjects with negative TST (n = 25), performed QFT-GIT
and were enrolled in this retrospective analysis (n = 169)
(Fig. 1). A group of 142 HCWs was excluded from the
study since they were screened only by IGRA because TST
was refused (n = 64, 45.1 %), contraindicated (n = 59,
41.5 %) or avoided for other motivations (n = 19, 13.4 %).
The time elapsed between TST and blood draw for QFT-
GIT was variable. In 30 cases blood for IGRA testing was
drawn within 15 days, in 38 cases within 6 months and in
17 within 1 year. In the cases with known positivity to TST
in the past, the time elapsed was longer than 1 year. The
Fisher exact test showed that there was not a statistically
significant correlation between time intervals (TST and
blood draw for QFT-GIT) and the probability of a positive
QFT-GIT result (p = 0.282).
The subjects with positivity for TST and IGRA under-
went a chest X-ray to exclude an active TB disease. In the
absence of clinical and radiographic signs of active TB,
they were considered to have a LTBI and underwent a
clinical follow up at 6, 12 and 24 months after diagnosis.
An infectious diseases consultant evaluated all LTBI cases
and the decision of prescribing prophylaxis was taken case
by case.
TST was performed by trained personnel following
standard procedures. Intradermal injection of 0.1 ml of
PPD (TUBERTEST®, Sanofi Pasteur MSD, France) con-
taining 5 tuberculin units was performed into the volar
surface of the forearm. The reaction to TST was assessed
Olivieri et al. Journal of Occupational Medicine and Toxicology  (2016) 11:29 Page 2 of 6
after 48 to 72 h from the injection by health-care workers
trained to read TST results, while self-reporting of results
was not allowed. Induration of 10 mm or more was con-
sidered a positive result in persons who had increased risk
factors to TB exposure such as HCWs according to CDC’s
interpretation criteria [1]. A diameter of 5 mm or more
was considered positive in HCWs after accidental contact
with infectious patients or materials (identified as
“contacts”).
The QuantiFERON®-TB Gold In-Tube test was per-
formed in accordance with the manufactures’s instructions.
Briefly, 1 mL of blood was sampled in each of the three
tubes containing no antigen (Nil Control tube), TB-specific
antigens (ESAT-6, CFP-10 and TB7.7; TB Antigen tube),
and positive control (Mitogen Control tube), respectively.
Tubes were incubated at 37 °C for 16–24 h before centrifu-
gation, and IFN-γ concentration (IU/ml) was measured by
ELISA following the manufacturer’s protocol. The test was
considered positive when IFN-γ concentration was ≥
0.35 IU/ml after correction for the negative control.
For each individual, information on age, gender, place
of birth, job category, workplace, previous exposure to
TB, family history of TB, prior TST results and BCG
vaccination was collected by clinical chart review and
vaccination records. BCG vaccination was mandatory in
Italy for HCWs until 2001, when it was restricted to
contacts and HCWs exposed to multidrug resistant
strains with a negative TST at first screening.
According to the retrospective observational nature of
the present study and to the authorizations signed by
the HCWs related to personal data management includ-
ing scientific research, formal ethical approval by local
Ethics Committee is not requested. Personal information
on the subjects included in the study was protected
according to Italian law [Italian Law decree n. 196, 30
June 2003 (article 24): http://www.camera.it/parlam/
leggi/deleghe/03196dl.htm.].
Statistical analysis
The concordance between the TST and QFT-GIT results
was measured by kappa (k) statistics. A k value ≤ 0.4 was
regarded as poor, > 0.8 as excellent, and in between as fair
to good agreement according to the Landis and Koch scale.
The Fisher exact test was used to compare the frequencies
of test results among different groups of participants.
Descriptive statistics were reported as mean values ± stand-
ard deviations for quantitative variables and as frequencies
and percentages for qualitative variables. A p value ≤ 0.05
was considered statistically significant. All statistical analysis
were performed by using GraphPad 6 software.
Results
Of the 2136 screened subjects, 1992 resulted TST-negative
(93.3 %) and 144 TST-positive (6.7 %) using the established
cut-off values. QFT-GIT was performed in all TST-positive
subjects, as well as in 25 randomly selected HCWs with a
Fig. 1 Study population flow chart. HCWs: Healthcare Workers; TST: Tuberculin Skin Test; QFT: Quantiferon; TB: Tuberculosis; LTBI: Latent
Tuberculosis Infection
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negative TST. Of the 144 TST-positive HCWs, 36 were
QFT-GIT positive (25 %), 106 negative (73.6 %) and two
indeterminate (1.4 %) therefore excluded from our analysis
(Fig. 1). Selected subjects with negative TST were all nega-
tive to the QFT-GIT test (Fig. 1). Among the 36 cases of
TST+/QFT-GIT+, 4 had radiological signs of previous TB
disease (0.2 % of the total HCWs evaluated) while 32 were
diagnosed as LTBI (1.5 % of the total HCWs evaluated).
Chest X-rays excluded an active TB disease in all cases of
positivity for both TSTand IGRA. All LTBI cases were eval-
uated by an infectious diseases consultant but in any case a
chemoprophylaxis was indicated. None of the TST positive
cases developed active TB in the following months/years.
Overall agreement between IGRA and TST was poor
(k = 0.092; 95 % Confidence Interval [CI]- 0.048–0.136,
p = 0.002) (Table 1). Discordance between the two tests
was significantly higher among BCG-vaccinated (86.3 %)
than unvaccinated subjects (52.8 %) (p < 0.001), regard-
less of time since vaccination (Table 2). As shown in
Table 2, more than 50 % of the HCWs had reported a his-
tory of BCG vaccination, while 25.3 % had never received
BCG. Nevertheless, a clear history of BCG vaccination
could not be retrieved in 23.3 % of the studied population.
No association between other occupational and demo-
graphic factors and test results was observed. Indeed, gen-
der (68.3 % were female), age (median age 44.4 years),
birth in high (9.8 %) or low (90.2 %) endemic places, work-
ing in high TB risk wards (10.6 %), previous exposure to
TB infectious patients or materials (22.5 %), and job
category (most of HCWs were nurses) did not represent
putative risk factors for a positive QFT-GIT test (Table 2).
The probability of a QFT-GIT positive result increased
with the TST diameter (p = 0.001; Table 3). Indeed,
HCWs with a TST <10 mm were all QFT-GIT negative,
while in those with a TST between 10 and 15 mm the
probability was 24.0 % and in those with TST diameter
>15 mm, it was 27.5 % (Table 3).
Discussion
Screening programs for LTBI among HCWs together with
TB infection-control measures represent an important tool
to reduce the risk of TB transmission in healthcare settings.
These screening strategies are also recommended in low
TB incidence countries, such as Italy, where an annual TB
incidence of 5.7 per 100,000 inhabitants has been estimated
[3]. Only a few studies have been conducted to assess the
outcome of a two-step LTBI screening strategy (TST plus
IGRA) among healthcare workers in Italy [21, 22]. The
present work shows the results of a two-step LTBI screen-
ing among HCWs in Siena University Hospital and pro-
vides an updated epidemiology of LTBI among Italian









Negative 25 (15.0) - 25 (15.0) 0.092b 0.002
Positive 106 (63.5) 36 (21.6) 142 (85.0)a
All 131 (78.4) 36 (21.6) 167 (100)
aTwo IGRA-indeterminate subjects were excluded
b95 % CI- 0.048–0.136
Table 2 Association of TST and QFT-GIT results with demo-
graphic and occupational characteristics of TST-positive HCWs
population





Female 97 (68.3) 22 (22.7) 75 (77.3) 0.304
Male 45 (31.7) 14 (31.1) 31 (68.9)
Age, years
19–29 2 (1.4) 0 (0.0) 2 (100.0) 0.272
30–39 40 (28.2) 8 (20.0) 32 (80.0)
40–49 50 (35.2) 10 (20.0) 40 (80.0)
50–59 43 (30.3) 15 (34.9) 28 (65.1)
≥ 60 7 (4.9) 3 (42.9) 4 (57.1)
Place of birth
High endemic 14 (9.8) 4 (28.6) 10 (71.4) 0.752
Low endemic 128 (90.2) 32 (25.0) 96 (75.0)
BCG vaccination
yes 73 (51.4) 10 (13.7) 63 (86.3) <0.001
no 36 (25.3) 17 (47.2) 19 (52.8)
unknown 33 (23.3) 9 (22.3) 24 (72.7)
Time since BCG vaccination, years
< 10 3 (4.1) 1 (33.3) 2 (66.7) 0.184
10–14 13 (17.8) 3 (23.1) 10 (76.9)
≥ 15 57 (40.1) 6 (10.5) 51 (89.5)
Previous TST
yes 95 (66.9) 23 (24.2) 72 (75.8) 0.685
no 47 (33.1) 13 (27.6) 34 (72.4)
TB contacts
yes 32 (22.5) 7 (21.8) 25 (78.2) 0.817
no 110 (77.5) 29 (26.4) 81 (73.6)
Job category
Physician 15 (10.6) 4 (26.7) 11 (73.3) 0.555
Nurse 66 (46.5) 13 (19.7) 53 (80.3)
Nurse assistant 29 (20.4) 8 (28.6) 20 (71.4)
Student 12 (8.5) 4 (33.3) 8 (66.7)
other 20 (14.0) 7 (35.0) 13 (65.0)
Ward
High TB risk 15 (10.6) 3 (20.0) 12 (80.0) 0.760
Low TB risk 127 (89.4) 33 (26.0) 94 (74.0)
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HCWs. In our setting, a global prevalence of LTBI of 1.5 %
was observed, consistent with other studies performed
among HCWs in areas with a low TB incidence (mean
value of 1 %, range 0.2–12 %) [8, 11, 23]. These data are
justified by the low circulation of M. tuberculosis in hospi-
tals of low TB prevalence countries that reduces the risk of
contact with infected patients.
In our study, 144 subjects were positive to the tuberculin
test, corresponding to the 6.7 %. In line with data reported
by other Italian and European studies [24–26], only the
22.2 % of TST positive HCWs also had a positive QFT-GIT
result. Our data also show that the probability of a QFT-
GIT positive result increased with TST diameter and this
correlation was already reported in previous studies among
HCWs [24, 27, 28].
A poor agreement was observed between the two tests
and discordant results (TST+/QFT-GIT-) occurred pri-
marily among BCG vaccinated subjects in line with what
was reported in other studies conducted in low TB preva-
lence countries [25, 29]. This is particularly relevant for
countries like Italy where BCG vaccination was mandatory
for HCWs until 2001, when it was restricted to defined
high TB risk categories only, based on risk assessment at
hospital level [30]. Of course, since the sensitivity of QFT-
GIT in infected individuals is not 100 %, caution should
be taken into account when interpreting discordant results
(TST+/QFT-GIT-) occurring in high risk HCWs [14, 18].
Another putative cause of TST+/QFT-GIT- results could
be the exposure to NTM [31]. These data strongly support
the added value of using both clinical tests, rather than
TST alone, for LTBI diagnosis.
Conclusion
Our data strongly support the added value of using QFT-
GIT test in TST-positive HCWs for LTBI diagnosis, espe-
cially in settings with a high rate of BCG vaccination. TST
is widely used as a first LTBI screening tool but the intro-
duction of IGRA as a second step assay in TST-positive
HCWs reduces the potential occurrence of “false posi-
tives” due to BCG vaccination or atypical mycobacteria in-
fections and improves the clinical management of LTBI
cases. In fact, the introduction of QFT-GIT test could re-
duce the number of unnecessary chest X-ray and avoid
the costs and toxicity associated with unnecessary treat-
ment. Despite the monocentric and observational nature
of the study, our results could help to better understand
factors influencing screening results and the optimal strat-
egy for LTBI diagnosis among HCWs. Absence of a true
gold standard test for LTBI represents a major challenge
for determining the accuracy of new LTBI tests, therefore
the choice of using a two-step strategy is also aimed at in-
creasing the accuracy level of the diagnostic workup, pro-
viding additional information for management and clinical
follow-up of LTBI cases.
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